LICORbio

Executive Summary

LICORbio is a US-based biotechnology company founded in 2017 that provides advanced imaging systems, reagents, and software for life science research. Its integrated platform covers quantitative Western blots, protein gels, ELISAs, tissue section imaging, and emerging 3D cell culture applications, offering high sensitivity and dynamic range. The company serves academic and biopharma researchers, competing with established players like Bio-Rad and Thermo Fisher. LICORbio's differentiation lies in its end-to-end ecosystem, which enhances data confidence and workflow efficiency. While the company remains private with limited disclosed financials, its focus on innovation positions it well in the growing life science tools market. We assign a conviction score of 65, reflecting potential catalysts but tempered by competitive and financial uncertainties.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation 3D cell culture imaging platform70% success
• Q1 2027Strategic partnership with a leading pharma company for workflow integration60% success